Published in Cancer Prev Res (Phila) on August 11, 2011
Aberrant expression of microRNAs in bladder cancer. Nat Rev Urol (2013) 1.74
CD24 induces expression of the oncomir miR-21 via Src, and CD24 and Src are both post-transcriptionally downregulated by the tumor suppressor miR-34a. PLoS One (2013) 1.51
Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling. PLoS One (2012) 1.26
MicroRNA-23b functions as a tumor suppressor by regulating Zeb1 in bladder cancer. PLoS One (2013) 1.23
Extracellular microRNAs in urologic malignancies: chances and challenges. Int J Mol Sci (2013) 1.11
Regulation of microRNAs by natural agents: new strategies in cancer therapies. Biomed Res Int (2014) 1.06
New perspectives of curcumin in cancer prevention. Cancer Prev Res (Phila) (2013) 1.05
Pure curcumin decreases the expression of WT1 by upregulation of miR-15a and miR-16-1 in leukemic cells. J Exp Clin Cancer Res (2012) 0.97
Differential expression of microRNAs in plasma of patients with laryngeal squamous cell carcinoma: potential early-detection markers for laryngeal squamous cell carcinoma. J Cancer Res Clin Oncol (2013) 0.95
MicroRNA expression patterns related to merkel cell polyomavirus infection in human merkel cell carcinoma. J Invest Dermatol (2013) 0.92
Health promoting effects of brassica-derived phytochemicals: from chemopreventive and anti-inflammatory activities to epigenetic regulation. Oxid Med Cell Longev (2013) 0.91
Contribution of microRNA-203 to the isoflurane preconditioning-induced neuroprotection. Brain Res Bull (2012) 0.89
Epigenetic impact of curcumin on stroke prevention. Metab Brain Dis (2014) 0.89
"Curcumin, the King of Spices": Epigenetic Regulatory Mechanisms in the Prevention of Cancer, Neurological, and Inflammatory Diseases. Curr Pharmacol Rep (2015) 0.88
Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells. Br J Cancer (2013) 0.88
miR-203 regulates cell proliferation through its influence on Hakai expression. PLoS One (2012) 0.88
Oral epithelial stem cells - implications in normal development and cancer metastasis. Exp Cell Res (2014) 0.84
MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin. PLoS One (2015) 0.84
Epigenetic regulation by selected dietary phytochemicals in cancer chemoprevention. Cancer Lett (2014) 0.84
Dietary phytochemicals as epigenetic modifiers in cancer: Promise and challenges. Semin Cancer Biol (2016) 0.83
ING1b-inducible microRNA203 inhibits cell proliferation. Br J Cancer (2013) 0.83
Mechanistic insights into the role of microRNAs in cancer: influence of nutrient crosstalk. Front Genet (2012) 0.83
Curcumin a potent cancer preventive agent: Mechanisms of cancer cell killing. Interv Med Appl Sci (2014) 0.83
MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells. J Exp Clin Cancer Res (2016) 0.82
Acetylation of p53 stimulates miRNA processing and determines cell survival following genotoxic stress. EMBO J (2013) 0.82
Manipulating the epigenome for the treatment of urological malignancies. Pharmacol Ther (2013) 0.81
Epigenetic regulation of miRNA-cancer stem cells nexus by nutraceuticals. Mol Nutr Food Res (2013) 0.81
Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. Aging (Albany NY) (2017) 0.79
Modulation of microRNAs by phytochemicals in cancer: underlying mechanisms and translational significance. Biomed Res Int (2015) 0.78
MicroRNA-4723 inhibits prostate cancer growth through inactivation of the Abelson family of nonreceptor protein tyrosine kinases. PLoS One (2013) 0.77
Curcumin potentiates antitumor activity of cisplatin in bladder cancer cell lines via ROS-mediated activation of ERK1/2. Oncotarget (2016) 0.76
Epigenetic reactivation of RASSF1A by phenethyl isothiocyanate (PEITC) and promotion of apoptosis in LNCaP cells. Pharmacol Res (2016) 0.75
Targeting microRNAs: a new action mechanism of natural compounds. Oncotarget (2016) 0.75
MicroRNA-203 mimics age-related aortic smooth muscle dysfunction of cytoskeletal pathways. J Cell Mol Med (2016) 0.75
Posttranscriptional deregulation of Src due to aberrant miR34a and miR203 contributes to gastric cancer development. BMB Rep (2013) 0.75
Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts. BMC Res Notes (2016) 0.75
The role of miR-24 as a race related genetic factor in prostate cancer. Oncotarget (2017) 0.75
EF24 Suppresses Invasion and Migration of Hepatocellular Carcinoma Cells In Vitro via Inhibiting the Phosphorylation of Src. Biomed Res Int (2016) 0.75
Pien Tze Huang inhibits the proliferation of colorectal cancer cells by increasing the expression of miR-34c-5p. Exp Ther Med (2017) 0.75
Antiproliferative activity of Haematoxylum brasiletto H. Karst. Pharmacogn Mag (2017) 0.75
Up-regulation of miR-21 decreases chemotherapeutic effect of dendrosomal curcumin in breast cancer cells. Iran J Basic Med Sci (2017) 0.75
Understanding the Role of Non-Coding RNAs in Bladder Cancer: From Dark Matter to Valuable Therapeutic Targets. Int J Mol Sci (2017) 0.75
MicroRNAs in Hearing Disorders: Their Regulation by Oxidative Stress, Inflammation and Antioxidants. Front Cell Neurosci (2017) 0.75
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell (2007) 38.42
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
The microRNA.org resource: targets and expression. Nucleic Acids Res (2007) 16.26
Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol (1997) 11.36
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol (2001) 11.35
Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res (2005) 9.80
MicroRNAs and cancer: short RNAs go a long way. Cell (2009) 7.25
Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res (2003) 5.72
A skin microRNA promotes differentiation by repressing 'stemness'. Nature (2008) 5.66
Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer (2008) 5.65
Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev (2003) 4.62
Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res (2008) 4.19
MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene (2008) 4.11
Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell (2008) 4.01
The hunting of the Src. Nat Rev Mol Cell Biol (2001) 3.64
MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol (2011) 3.57
miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis (2009) 3.45
The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene (2005) 3.42
Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta (2002) 3.33
miR-203 represses 'stemness' by repressing DeltaNp63. Cell Death Differ (2008) 2.86
Focus on bladder cancer. Cancer Cell (2004) 2.59
Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res (2009) 2.58
Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer (2005) 2.49
The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol (2006) 2.19
Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis. Clin Cancer Res (2010) 2.07
Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther (2008) 1.92
AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci (2005) 1.72
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol (2009) 1.61
Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res (2007) 1.60
Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene (2001) 1.58
Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene (2008) 1.57
Src kinase contributes to the metastatic spread of carcinoma cells. Oncogene (2002) 1.51
Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm Res (2010) 1.40
Cellular signaling perturbation by natural products. Cell Signal (2009) 1.36
Curcumin is a potent DNA hypomethylation agent. Bioorg Med Chem Lett (2008) 1.31
Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther (2007) 1.27
Development of curcumin as an epigenetic agent. Cancer (2010) 1.18
Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int J Oncol (2002) 1.11
Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells. Med Oncol (2009) 1.04
Elevated expression of pp60c-src in low grade human bladder carcinoma. Cancer Res (1992) 0.98
Pathways of metastasis suppression in bladder cancer. Cancer Metastasis Rev (2009) 0.98
Effects of curcumin on bladder cancer cells and development of urothelial tumors in a rat bladder carcinogenesis model. Cancer Lett (2008) 0.97
Preclinical assessment of curcumin as a potential therapy for B-CLL. Am J Hematol (2007) 0.94
Diet, microRNAs and prostate cancer. Pharm Res (2010) 0.93
Intravesical therapy for bladder cancer. Expert Opin Pharmacother (2010) 0.90
[Induction of apoptosis in human nasopharyngeal carcinoma cell line CNE-2Z by curcumin]. Ai Zheng (2004) 0.78
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med (2005) 28.73
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature (2003) 22.89
Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med (2003) 14.60
MethPrimer: designing primers for methylation PCRs. Bioinformatics (2002) 14.48
TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol (2007) 11.14
The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol (2009) 6.74
MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci U S A (2008) 6.38
Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci U S A (2006) 4.90
IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med (2007) 3.69
From molecular to macroscopic via the rational design of a self-assembled 3D DNA crystal. Nature (2009) 3.18
Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol (2012) 3.09
Hormonal, cellular, and molecular control of prostatic development. Dev Biol (2003) 2.67
IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J Immunol (2009) 2.39
Coordination of p300-mediated chromatin remodeling and TRAP/mediator function through coactivator PGC-1alpha. Mol Cell (2003) 2.31
Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis. Clin Cancer Res (2010) 2.07
Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst (2005) 2.03
Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. Eur J Radiol (2006) 1.95
Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. Int J Nanomedicine (2012) 1.94
Aurora kinase inhibitors--rising stars in cancer therapeutics? Mol Cancer Ther (2010) 1.91
E protein silencing by the leukemogenic AML1-ETO fusion protein. Science (2004) 1.89
The relationship between global methylation level, loss of heterozygosity, and microsatellite instability in sporadic colorectal cancer. Clin Cancer Res (2005) 1.85
MED1/TRAP220 exists predominantly in a TRAP/ Mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription. Mol Cell (2005) 1.85
'Social evils' and harm reduction: the evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam. Addiction (2007) 1.85
DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog (2002) 1.83
Changes of functional connectivity of the motor network in the resting state in Parkinson's disease. Neurosci Lett (2009) 1.78
The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression. J Natl Cancer Inst (2013) 1.76
Silver nanoparticles in therapeutics: development of an antimicrobial gel formulation for topical use. Mol Pharm (2009) 1.75
Chiral separation of tamsulosin isomers by HPLC using cellulose tris (3,5-dimethhylphenylcarbamate) as a chiral stationary phase. J Pharm Biomed Anal (2004) 1.75
Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res (2006) 1.73
Growth arrest induced by C75, A fatty acid synthase inhibitor, was partially modulated by p38 MAPK but not by p53 in human hepatocellular carcinoma. Cancer Biol Ther (2006) 1.70
Structural basis for modulation of Kv4 K+ channels by auxiliary KChIP subunits. Nat Neurosci (2006) 1.70
MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer (2010) 1.70
Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer (2011) 1.69
Fragile X mental retardation protein controls gating of the sodium-activated potassium channel Slack. Nat Neurosci (2010) 1.67
Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patients. Cochrane Database Syst Rev (2015) 1.67
Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer. Cancer Prev Res (Phila) (2013) 1.66
The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci (2007) 1.66
A DNAzyme that walks processively and autonomously along a one-dimensional track. Angew Chem Int Ed Engl (2005) 1.65
Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res (2006) 1.65
The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity (2010) 1.64
Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol (2011) 1.63
Neuroimmunophilin ligands protect cavernous nerves after crush injury in the rat: new experimental paradigms. Eur Urol (2006) 1.63
miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J Biol Chem (2011) 1.63
Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res (2008) 1.58
MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res (2011) 1.57
Robust discrimination between self and non-self neurites requires thousands of Dscam1 isoforms. Nature (2009) 1.54
Reducing HIV infection among new injecting drug users in the China-Vietnam Cross Border Project. AIDS (2007) 1.53
MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis (2011) 1.51
Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J Am Chem Soc (2012) 1.50
Mir-144 selectively regulates embryonic alpha-hemoglobin synthesis during primitive erythropoiesis. Blood (2008) 1.50
Pseudomonas aeruginosa exotoxin pyocyanin causes cystic fibrosis airway pathogenesis. Am J Pathol (2009) 1.47
miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res (2012) 1.46
BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer. Int J Cancer (2006) 1.46
Impact of warming blood transfusion and infusion toward cerebral oxygen metabolism and cognitive recovery in the perioperative period of elderly knee replacement. J Orthop Surg Res (2014) 1.45
Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int J Cancer (2008) 1.45
BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis (2009) 1.44
Effective connectivity of brain networks during self-initiated movement in Parkinson's disease. Neuroimage (2010) 1.44
A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat Immunol (2010) 1.44
The E-cadherin -160 C/A polymorphism and prostate cancer risk in white and black American men. J Urol (2006) 1.43
Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res (2006) 1.41
Depression in the United States and Japan: gender, marital status, and SES patterns. Soc Sci Med (2005) 1.41
Heat stress-induced response of the proteomes of leaves from Salvia splendens Vista and King. Proteome Sci (2013) 1.41
Parkinson's disease patients with pain suffer from more severe non-motor symptoms. Neurol Sci (2014) 1.40
Coronary computed tomography angiography---a promising imaging modality in diagnosing coronary artery disease. J Chin Med Assoc (2008) 1.40
MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. Carcinogenesis (2011) 1.39
Antitumor effect of dsRNA-induced p21(WAF1/CIP1) gene activation in human bladder cancer cells. Mol Cancer Ther (2008) 1.39
Induction of blood brain barrier tight junction protein alterations by CD8 T cells. PLoS One (2008) 1.38
Pores and ridges: high-resolution fingerprint matching using level 3 features. IEEE Trans Pattern Anal Mach Intell (2007) 1.35
Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer. PLoS One (2012) 1.35
Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ Res (2012) 1.35
PGDB: a curated and integrated database of genes related to the prostate. Nucleic Acids Res (2003) 1.35
Hematopoietic gene expression profile in zebrafish kidney marrow. Proc Natl Acad Sci U S A (2004) 1.31
Structural and functional organization of TRAP220, the TRAP/mediator subunit that is targeted by nuclear receptors. Mol Cell Biol (2004) 1.31
Correlates of HIV status among injection drug users in a border region of southern China and northern Vietnam. J Acquir Immune Defic Syndr (2005) 1.31
Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc Natl Acad Sci U S A (2014) 1.30